EMA Backs Expanded Abiraterone Prostate Cancer Use
The EU medicines committee recommended new indications for Abiraterone Mylan in hormone-sensitive and castration-resistant prostate cancer.
Updated on Nov. 2, 2026 in Cancer
On 17 September 2026, the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending a change to the marketing authorisation for abiraterone acetate (Abiraterone Mylan), held by Mylan Pharmaceuticals Limited. The change adds two new indications for newly diagnosed hormone-sensitive prostate cancer and modifies an existing one.
Why it matters
The recommendation would widen the set of prostate cancer patients in the European Union eligible for abiraterone-based treatment, including those with high-risk non-metastatic disease and those with metastatic castration-resistant disease. The opinion is a step toward a binding European Commission decision.
The CHMP positive opinion is a recommendation rather than a final authorisation, with the European Commission decision normally issued 67 days after adoption. The exact clinical recommendations for use remain unpublished until the updated product characteristics appear on the EMA website.
The players
European Medicines Agency (EMA)
The EU agency responsible for the scientific evaluation and supervision of medicines across the European Union, whose Committee for Medicinal Products for Human Use issued the opinion.
Mylan Pharmaceuticals Limited
The marketing authorisation holder for Abiraterone Mylan, a generic version of abiraterone acetate, operating as part of the global Mylan generics group.
The details
Abiraterone Mylan is indicated with prednisone or prednisolone for the listed treatments. The updated indications cover newly diagnosed high-risk non-metastatic and metastatic hormone-sensitive prostate cancer used with androgen deprivation therapy, as well as metastatic castration-resistant disease in patients who are asymptomatic or mildly symptomatic after ADT failure or who have progressed after docetaxel-based chemotherapy.
Timeline
17 September 2026: CHMP adopts positive opinion recommending the change to the marketing authorisation.
About 67 days after the opinion: normal timeframe for the European Commission decision.
Patient Context
Under the EU centralised marketing authorisation procedure administered by the European Medicines Agency, this opinion extends an already authorised generic abiraterone product to additional prostate cancer patient groups. It follows the standard pathway in which a CHMP opinion precedes a binding European Commission decision.
If approved, the expanded indications could give patients with newly diagnosed or advanced prostate cancer in the European Union access to abiraterone-based treatment in additional clinical situations. Patients and clinicians should consult the updated summary of product characteristics once it is published for detailed use guidance.
The takeaway
Expanded indications for abiraterone reflect how EU prostate cancer treatment is being extended to earlier and later disease stages. Patients should discuss any new option with their oncologist once the updated product information is available.
What happens next
The European Commission decision on the change to the Abiraterone Mylan marketing authorisation is expected about 67 days after the 17 September 2026 opinion, after which the updated summary of product characteristics will be published on the EMA website.
Further reading
Explore more on Cancer developments and treatment approvals.
More information
Read the report on the EMA CHMP opinion for Abiraterone Mylan.
Source note: This article includes information reported by Firstwordpharma.
